PSFG
UTHR icon

Park Square Financial Group’s United Therapeutics UTHR Stock Holding History

Park Square Financial Group’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.33K Sell
8
-7
-47% -$3.94K 0.04% 131
2026
Q1 		$8.89K Sell
15
-31
-67% -$15.4K 0.07% 100
2025
Q4 		$16.2K Buy
46
+32
+229% +$14.9K 0.1% 106
2025
Q3 		$5.87K Sell
14
-385
-96% -$129K 0.03% 192
2025
Q2 		$115K Buy
399
+92
+30% +$27.5K 0.08% 177
2025
Q1 		$94.6K Sell
307
-309
-50% -$106K 0.08% 179
2024
Q4 		$217K Buy
+616
New +$226K 0.15% 82

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Park Square Financial Group's UTHR Position: Q2 2026 in Review

Park Square Financial Group reduced its United Therapeutics (UTHR) stake by 47% in Q2 2026, selling an estimated $3.94K and leaving 8 shares worth $4.33K. The position accounts for 0.04% of the portfolio, ranked #131.

Park Square Financial Group first reported a position in UTHR in Q4 2024 and has held it in 7 quarters since. The position peaked at $217K in Q4 2024. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Park Square Financial Group held 8 shares of United Therapeutics worth $4.33K as of Q2 2026.
  • Park Square Financial Group sold 7 United Therapeutics shares in Q2 2026, an estimated $3.94K.
  • United Therapeutics made up 0.04% of Park Square Financial Group's portfolio in Q2 2026, its #131 holding.
  • Park Square Financial Group first reported a position in United Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • Park Square Financial Group's United Therapeutics position peaked at $217K in Q4 2024.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Park Square Financial Group's 13F filing for Q2 2026, filed 31 Jul 2026.